CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug trial halted early – what we know
Disease control TerminatedThis study tested a new drug called JBH492 in 25 people with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL). The main goal was to check safety and find the right dose. The trial was stopped early, so results are limited.
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 04:35 UTC
-
Promising combo study halted early for blood cancer patients
Disease control TerminatedThis early-stage study tested a combination of two drugs, tafasitamab and parsaclisib, in 54 adults with relapsed or treatment-resistant non-Hodgkin lymphoma or chronic lymphocytic leukemia. The main goals were to check safety and find the right dose. The study was terminated ear…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 17, 2026 04:35 UTC
-
Two-Drug combo shows promise in Hard-to-Treat leukemia, but trial halted early
Disease control TerminatedThis study tested a two-drug combination (ibrutinib followed by venetoclax) in 30 adults with chronic lymphocytic leukemia (CLL) that had returned or stopped responding to prior treatment. The goal was to see if the drugs could work together to clear cancer cells from the body an…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
Blood cancer transplant study tests safer GVHD prevention
Disease control TerminatedThis study looked at people with blood cancers receiving a stem cell transplant from an unrelated donor. The goal was to compare two drug combinations (cyclosporine plus sirolimus with either MMF or post-transplant cyclophosphamide) to prevent graft-versus-host disease (GVHD), a …
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:33 UTC
-
Promising combo for CLL falls short: study stopped early
Disease control TerminatedThis study tested whether adding pirtobrutinib to venetoclax could clear remaining cancer cells in people with CLL/SLL who still had detectable disease after venetoclax alone. Only 3 adults enrolled before the study was stopped. The goal was to see if the combination could make t…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Promising CLL combo trial halted early after enrolling just 5 patients
Disease control TerminatedThis study tested a two-drug approach—pembrolizumab (an immunotherapy) followed by ibrutinib—in people with previously untreated, high-risk chronic lymphocytic leukemia (CLL). The goal was to see if the combination could improve the body's immune function and shrink or control th…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Promising CLL drug trial halted early – what we learned
Disease control TerminatedThis study tested the drug umbralisib in 12 people with chronic lymphocytic leukemia (CLL) who had not received prior treatment. The goal was to see how well the drug shrank or controlled the cancer and to check for side effects. The trial was stopped early, but results showed so…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 04, 2026 16:31 UTC